Low yield of head CT in cirrhotic patients presenting with hepatic encephalopathy.
cirrhosis
hepatic encephalopathy
liver cirrhosis
Journal
BMJ open gastroenterology
ISSN: 2054-4774
Titre abrégé: BMJ Open Gastroenterol
Pays: England
ID NLM: 101660690
Informations de publication
Date de publication:
06 2021
06 2021
Historique:
received:
21
01
2021
revised:
18
04
2021
accepted:
19
04
2021
entrez:
4
6
2021
pubmed:
5
6
2021
medline:
25
11
2021
Statut:
ppublish
Résumé
The utility of routine head CT (HCT) in hepatic encephalopathy (HE) evaluation is unclear. We investigated HCT yield in detecting acute intracranial abnormalities in cirrhotic patients presenting with HE. Retrospective review of cirrhotic patient encounters with HE between 2016 and 2018 at Beaumont Health, in Michigan was performed. A low-risk (LR) indication for HCT was defined as altered mental status (AMS), which included dizziness and generalised weakness. A high-risk (HR) indication was defined as trauma/fall, syncope, focal neurological deficits (FNDs) or headache. Descriptive statistics and univariate/multivariate analyses by logistic regression were performed using SPSS to identify HCT abnormality correlates. Five hundred twenty unique encounters were reviewed. Mean age was 63.4 (12.1) years, 162 (37.5%) had alcoholic cirrhosis and median Model for End-Stage Liver Disease (MELD)-score was 17 (13-23). LR indication was reported in 408 (78.5%) patients and FNDs reported in 24 (4.6%) patients. Only 13 (2.5%) patients were found to have an acute intracranial pathology (seven haemorrhagic stroke, two ischaemic stroke, four subdural haematoma). Aspirin use prior to presentation (aOR 4.6, 95% CI 1.1 to 19.2), and HR indication (aOR 7.3, 95% CI 2.3 to 23.8) were independent correlates of acute intracranial pathology on HCT. Age, sex, MELD-score, haemoglobin, platelet count, race and cirrhosis aetiology did not correlate with HCT abnormalities. Number needed to screen to identify one acute pathology was 14 in HR indications versus 82 for LR indications. Routine HCTs in cirrhotic patients presenting with HE with AMS in the absence of history of trauma, headache, syncope, FNDs or aspirin use is of low diagnostic yield.
Sections du résumé
GOALS AND BACKGROUND
The utility of routine head CT (HCT) in hepatic encephalopathy (HE) evaluation is unclear. We investigated HCT yield in detecting acute intracranial abnormalities in cirrhotic patients presenting with HE.
STUDY
Retrospective review of cirrhotic patient encounters with HE between 2016 and 2018 at Beaumont Health, in Michigan was performed. A low-risk (LR) indication for HCT was defined as altered mental status (AMS), which included dizziness and generalised weakness. A high-risk (HR) indication was defined as trauma/fall, syncope, focal neurological deficits (FNDs) or headache. Descriptive statistics and univariate/multivariate analyses by logistic regression were performed using SPSS to identify HCT abnormality correlates.
RESULTS
Five hundred twenty unique encounters were reviewed. Mean age was 63.4 (12.1) years, 162 (37.5%) had alcoholic cirrhosis and median Model for End-Stage Liver Disease (MELD)-score was 17 (13-23). LR indication was reported in 408 (78.5%) patients and FNDs reported in 24 (4.6%) patients. Only 13 (2.5%) patients were found to have an acute intracranial pathology (seven haemorrhagic stroke, two ischaemic stroke, four subdural haematoma). Aspirin use prior to presentation (aOR 4.6, 95% CI 1.1 to 19.2), and HR indication (aOR 7.3, 95% CI 2.3 to 23.8) were independent correlates of acute intracranial pathology on HCT. Age, sex, MELD-score, haemoglobin, platelet count, race and cirrhosis aetiology did not correlate with HCT abnormalities. Number needed to screen to identify one acute pathology was 14 in HR indications versus 82 for LR indications.
CONCLUSION
Routine HCTs in cirrhotic patients presenting with HE with AMS in the absence of history of trauma, headache, syncope, FNDs or aspirin use is of low diagnostic yield.
Identifiants
pubmed: 34083228
pii: bmjgast-2021-000609
doi: 10.1136/bmjgast-2021-000609
pmc: PMC8174513
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: None declared.
Références
Ann Hepatol. 2018 Aug 24;17(5):810-814
pubmed: 30145558
Pharmacoepidemiol Drug Saf. 2012 Dec;21(12):1334-43
pubmed: 23080224
Hepatology. 2014 Aug;60(2):715-35
pubmed: 25042402
J Am Coll Radiol. 2015 May;12(5):453-7
pubmed: 25841864
Clin Gastroenterol Hepatol. 2015 Jan;13(1):165-9
pubmed: 24907500
Am J Med Sci. 2016 May;351(5):459-66
pubmed: 27140703
Liver Transpl. 2018 Jul;24(7):872-880
pubmed: 29624871
J Clin Transl Hepatol. 2017 Jun 28;5(2):142-151
pubmed: 28660152
Am J Gastroenterol. 2001 Sep;96(9):2718-23
pubmed: 11569701
J Hepatol. 2018 Aug;69(2):406-460
pubmed: 29653741
PLoS One. 2019 Oct 3;14(10):e0223380
pubmed: 31581275
Drugs. 2019 Feb;79(Suppl 1):5-9
pubmed: 30706420
Clin Gastroenterol Hepatol. 2012 Sep;10(9):1034-41.e1
pubmed: 22642955
BMC Gastroenterol. 2008 May 24;8:16
pubmed: 18501016